A comparison of cryopreserved vein allografts and prosthetic grafts for hemodialysis access

Annals of Vascular Surgery

Volumn 19, Issue 5, 2005, Pages 686-691

  Madden, Robert L ^a,b,c   Lipkowitz, George S ^a,b   Browne, Barry J ^a,b   Kurbanov, Alexander ^a  

^a BAYSTATE MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLITEF;

AFRICAN AMERICAN; AGED; ALLOGRAFT; ARM; ARTERIOVENOUS FISTULA; ARTERY OCCLUSION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOPRESERVATION; DEATH; DOPPLER FLOWMETRY; ELBOW; EVALUATION; FEMALE; FISTULA; FOOD AND DRUG ADMINISTRATION; HEMODIALYSIS; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECORDING; STATISTICAL SIGNIFICANCE; THROMBECTOMY; THROMBOSIS; VASCULAR PATENCY; VASCULAR TISSUE; VEIN GRAFT;

EID: 24044448658     PISSN: 08905096     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10016-005-6621-2     Document Type: Article

References (15)

1. United States Renal Data System, www.usrds.org.
2. Hsu CY, Vittinghoff E, Lin F, et al. The incidence of endstage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 2004;141:95-101.
3. Schwab SJ.. Improving access patency: pre-end-stage renal disease strategies. J Am Soc Nephrol 1998;9:S124-S129.
4. Gibson KD, Gillen DL, Caps MT, et al. Vascular access survival and incidence of revisions: a comparison of prosthetic grafts, simple autogenous fistulas, and venous transposition fistulas from the United States Renal Data System dialysis morbidity and mortality study. J Vasc Surg 2001;34:694-700.
5. Miller PE, Carlton D, Deierhoi MH, et al. Natural history of arteriovenous grafts in hemodialysis patients. Am J Kidney Dis 2000;36:68-74.
6. Matsuura JH, Rosenthal D, Wellons ED, et al. Hemodialysis graft infections treated with cryopreserved femoral vein. Cardiovasc Surg 2002;10:561-565.
7. Lin PH, Brinkman WT, Terramani TT, et al. Management of infected hemodialysis access grafts using cryopreserved human vein allografts. Am J Surg 2002;184:31-36.
8. Madden RL, Lipkowitz GS, Browne BJ, et al. Experience with cyropreserved cadaveric femoral vein allografts used for hemodialysis access. Ann Vasc Surg 2004;18:453-458.
9. CryoLife. Clinical program 301. Allograft veins protocol. Available at: www.cryolife.com.
10. Sidawy AN, Gray R, Besarab A, et al. Recommended standards for reports dealing with arteriovenous hemodialysis accesses. J Vasc Surg 2002;35:603-610.
11. Martin RS, Edwards WH, Mulherin JL, et al. Cryopreserved saphenous vein allografts for below-knee lower extremity revascularization. Ann Surg 1994;219:664-672.
12. Iaffaldano RA, Lewis BE, Johnson SA, et al. Patency of cryopreserved saphenous vein grafts as conduits for coronary artery bypass surgery. Chest 1995;108:725-729.
13. Benedetto B, Lipkowitz G, Madden R, et al. Use of cryopreserved cadaveric vein allograft for hemodialysis access precludes kidney transplantation because of allosensitization. J Vasc Surg 2001;34:139-142.
14. Madden R, Lipkowitz G, Benedetto B, et al. Decellularized cadaver vein allografts used for hemodialysis access do not cause allosensitization or preclude kidney transplantation. Am J Kidney Dis 2002;40:1240-1243.
15. Bolton WD, Cull DL, Taylor SM, et al. The use of cryopreserved femoral vein grafts for hemodialsis access in patients at high risk for infection: a word of caution. J Vasc Surg 2002;36:464-468.